Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.50 |
| ▸ | GRK5 | P34947 | 1/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22473631 | 0.83 | MAPT (0.51) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL28996878 | 0.83 | MAPT (0.51) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL27546495 | 0.80 | MAPT (0.49) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL13106368 | 0.80 | MAPT (0.49) | MAPTCHEK1DAPK3GRK5LIMK1 | |
| SCHEMBL585538 | 0.79 | MAPT (0.48) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL589194 | 0.79 | MAPT (0.48) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL27566551 | 0.79 | MAPT (0.48) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL2842932 | 0.79 | MAPT (0.48) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL27566549 | 0.77 | MAPT (0.46) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL2850485 | 0.76 | ELANE (0.47) | MAPTALDH1A1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114394935-A | Improved preparation method of pazopanib key intermediate | 南京亿华药业有限公司 | 2022-04-26 | — | — | CN | claimed |
| CN-109212042-B | Analysis method for determining toxicity impurities of pezopyr hydrochloride gene by adopting liquid chromatography-mass spectrometry | 齐鲁制药有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-109212042-A | A kind of analysis method using liquid chromatography and mass spectrometry hydrochloric acid training azoles Pa Nijiyin toxic impurities | 齐鲁制药有限公司 | 2019-01-15 | — | — | CN | claimed |
| EP-2935250-B1 | PROCESS FOR THE PREPARATION OF PAZOPANIB OR SALTS THEREOF | SUN PHARMACEUTICAL IND LTD (IN) | 2018-03-28 | — | — | EP | claimed |
| US-9802923-B2 | Process for the preparation of pazopanib or salts thereof | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-10-31 | — | — | US | claimed |
| CN-103319410-B | A kind of synthetic method of indazole compound | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) | 2016-04-06 | — | — | CN | claimed |
| US-20150329526-A1 | PROCESS FOR THE PREPARATION OF PAZOPANIB OR SALTS THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2015-11-19 | — | — | US | claimed |
| EP-2935250-A1 | PROCESS FOR THE PREPARATION OF PAZOPANIB OR SALTS THEREOF | Ranbaxy Laboratories Limited (IN) | 2015-10-28 | — | — | EP | claimed |
| WO-2014097152-A1 | PROCESS FOR THE PREPARATION OF PAZOPANIB OR SALTS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2014-06-26 | — | — | WO | claimed |
| CN-103319410-A | Synthesis method of indazole compound | TIANJIN INST PHARM RESEARCH | 2013-09-25 | — | — | CN | claimed |
| CN-117924177-A | Preparation method of pazopanib intermediate 2, 3-dimethyl-6-amino-2H-indazole and analogues thereof | 南京杰运医药科技有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240050429-A1 | PAZOPANIB PHARMACEUTICAL COMPOSITION, INJECTION AND PREPARATION METHOD AND USE THEREOF | Qx Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| US-20230026808-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ISCHEMIA-REPERFUSION INJURY AND/OR LUNG INJURY | YALE UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-20230026808-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ISCHEMIA-REPERFUSION INJURY AND/OR LUNG INJURY | YALE UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-11427570-B2 | Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof | LAURUS LABS LIMITED (IN) | 2022-08-30 | — | — | US | disclosed |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | disclosed |
| CN-1549813-A | Pyrimidinamines as angiogenesis modulators | — | 2004-11-24 | — | — | CN | disclosed |
| WO-2003106416-A2 | CHEMICAL PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-24 | — | — | WO | disclosed |
| EP-1343782-A1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002059110-A1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | GLAXO GROUP LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | TYMS, TYMP, DPYD | MAPT 3924/4885CHEK1 500/4885DAPK3 513/4885 |
| US-20230026808-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ISCHEMIA-REPERFUSION INJURY AND/OR LUNG INJURY | DAPK3, PAK3, MAVS | MAPT 585/4885CHEK1 328/4885DAPK3 1/4885 |
| US-11427570-B2 | Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof | JAK2, SF3B5, PDGFRB | MAPT 4359/4885CHEK1 2277/4885DAPK3 2524/4885 |
| US-20150329526-A1 | PROCESS FOR THE PREPARATION OF PAZOPANIB OR SALTS THEREOF | ABL1, PDGFRB, PDGFRA | MAPT 4012/4885CHEK1 568/4885DAPK3 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.